Research programme: immuno-oncology therapeutics - Tangram Therapeutics
Latest Information Update: 07 Oct 2025
At a glance
- Originator e-Therapeutics
- Developer Tangram Therapeutics
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer